CYP cynata therapeutics limited

IPSC - MSC for bowel disease

  1. 203 Posts.
    lightbulb Created with Sketch.  20
    Marhttps://stemcellsjournals.onlinelibrary.wiley.com/doi/full/10.1002/sctm.17-0305%20%20
    Conclusion

    These studies are the first to demonstrate the equivalence of iMSC and adMSC for treatment of IBD, in a widely used rodent DSS colitis model. In all aspects evaluated, iMSC were equally potent in terms of suppressing intestinal inflammation and stimulating intestinal healing. These studies also revealed a significant stimulatory effect of iMSC cellular therapy on epithelial proliferation and angiogenesis, and restoration of normal microbiome populations.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Last
1.2¢
Change
0.000(0.00%)
Mkt cap ! $2.921M
Open High Low Volume
1.2¢ 1.2¢ 1.2¢ 52.60K

Buyers (Bids)

Vol. Price($)
253911 1.2¢
 

Sellers (Offers)

Price($) Vol.
1.3¢ 295000
Last trade - 09.59am 31/07/2026 (20 minute delay) ?
CYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.